Sanofi
 
3Q Revenues: €9.6 billion (+3%)

3Q Earnings: €2.1 billion  (+5%)

YTD Revenues: €27.8 billion (+4%)

YTD Earnings: €5.7 billion (+4%)

Comments: Pharmaceutical sales were €7.3 billion (+3%). Diabetes sales were €1.9 billion, down 7%, as a result of lower U.S. sales of Lantus (worldwide sales -11% to €1.6 billion). Genzyme sales were €923 million in the quarter, up 33%, with strong momentum driven by Multiple Sclerosis products and Aubagio sales up 79% to €225 million. Vaccines sales were €1.7 billion, up 6%, mainly driven by Emerging Markets. Oncology sales were €376 million, up 5%. Generics sales were up 7% to €452 million. Results stated at constant exchange rates.